The nomenclature International Nonproprietary Names (INN), or DCI in French, identifies pharmaceutical substances or active pharmaceutical ingredients in a unique way.

Thus, each INN is defined by a unique name [generic name] and recognized worldwide.

This nomenclature allows:

  • Clearly identify substances to safely prescribe and deliver drugs to patients regardless of geographic area

  • To facilitate exchanges between health professionals and researchers around the world.

To date, the nomenclature lists nearly 7,000 appellations. Every year manufacturers and inventors submit new requests. These are examined, along with the proposal and publication of an INN. If no objection is raised, the name obtains the status of "Recommended INN".

The use of INNs is normally required by national law. Moreover, the DCIs and the names of the various national systems [British Approved Names (BAN), French common denominations (DCF), Japanese Adopted Names (JAN) and United States Adopted Names (USAN),…] are, with rare exceptions, identical.

Documentation: https: // www. who.int/medicines/services/inn/innguidance/en/

Did this answer your question?